1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Indoco Remedies Limited

Indoco Remedies Limited

223.45
INR
-2.05
(-0.91%)
0.36EPS
369.60P/E
22.03BMarket Cap
Oct 27Next Earn
Indoco Remedies Limited
BSE:INDOCO
(Bombay Stock Exchange)

Recent

price

223.45

P/E

ratio

369.60

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
52.2
61.72
68.45
79.5
93
109.4
113.66
110.44
103.81
117.2
132.28
163.18
177.98
194.05
178.02
194.34
209.99
Revenue per Share
5.55
5.03
4.64
6.29
8.99
8.89
8.36
4.47
-0.32
2.62
10.1
16.8
15.44
10.68
-8
-10.31
0.65
Basic EPS, GAAP
-4.66
7.5
7.45
10.72
11.83
12.18
9.62
13.32
14.56
13.33
8.93
18.86
19.41
16.86
9.84
24.53
- -
Free Cash Flow per Basic Share
1.09
1.24
1.27
1.29
1.64
3.58
0.26
1.92
1.22
0.36
0.3
1.5
2.25
2.25
1.51
0.21
- -
Dividend per Share
38
41.23
44.94
49.61
57.27
62.56
70.68
73.25
71.69
73.75
83.45
98.17
111.58
120.44
110.89
101.9
- -
Book Value per Share
35.18
37.55
39.92
44.29
48.43
52.99
60.11
61.58
61.36
63.82
74.27
88.19
98.1
100.04
90.03
80.1
- -
Tangible Book Value per Share
92
92
92
92
92
92
92
92
91
92
92
92
92
92
92
92
87
Basic Weighted Avg Shares
4,811
5,688
6,308
7,326
8,570
10,081
10,474
10,177
9,421
10,800
12,186
15,037
16,400
17,882
16,413
17,929
18,283
Sales/Revenue/Turnover
11.4
11.6
11.09
12.36
14.42
11.19
8
6.37
-0.99
4.48
13.06
14.65
12.05
7.99
-0.89
0.86
1.86
Operating Margin (%)
135
192
237
309
471
607
633
677
716
708
731
772
706
919
983
1,069
1,313
Depreciation Expense
511
463
427
580
828
819
771
412
-29
241
930
1,548
1,423
985
-737
-951
56
Net Income, GAAP
9.66
9.6
11.92
19.75
24.4
17.17
15.26
14.95
- -
15.59
29.51
34.57
26.22
28.57
- -
- -
60.66
Effective Tax Rate (%)
10.63
8.15
6.77
7.91
9.66
8.13
7.36
4.04
-0.31
2.23
7.64
10.29
8.67
5.51
-4.49
-5.31
0.31
Profit Margin (%)
1,049
797
762
1,024
1,306
1,616
1,817
1,216
926
1,041
2,156
3,488
3,891
3,423
1,933
1,408
- -
Working Capital
540
462
274
138
128
379
1,323
1,233
1,287
1,024
1,039
1,068
1,585
3,641
5,426
5,584
- -
LT Debt
3,502
3,800
4,144
4,574
5,277
5,765
6,513
6,750
6,606
6,796
7,690
9,046
10,283
11,105
10,184
9,321
- -
Total Equity
12.34
12.94
12.31
14.03
15.79
13.76
8.49
5.28
- -
3.33
10.17
13.01
11.71
6.77
- -
- -
- -
Return on Invested Capital (%)
12.84
13.27
8.53
12.65
15.36
13.64
10.85
5.87
- -
4.5
10.87
15.07
12.67
7.94
- -
- -
- -
Return on Capital (%)
15.47
12.69
10.76
13.31
16.82
14.84
12.55
6.21
-0.43
3.6
12.85
18.5
14.72
9.21
-6.92
-9.7
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
5,314
- -
LT Borrowings
- -
5,160
- -
LT Finance Leases
- -
423
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
92
92
92
Market Capitalization
21,639
15,195
22,027

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
11,934
- -
Cash, Cash Equivalents & STI
- -
458
- -
Accounts Receivable, Net
- -
4,892
- -
Inventories
- -
4,052
- -
Total Current Liabilities
- -
10,525
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
5,314
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.3%
4.51%
-8.47%
Free Cash Flow
19.4%
41.8%
149.39%
Net Income, GAAP
-92.27%
-23.68%
29.03%
Sales/Revenue/Turnover
6.36%
8.5%
9.24%
Total Cash Common Dividend
74.19%
65.13%
-86.26%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
4,243
4,307
4,025
3,839
16,413
2026
4,309
4,718
4,343
4,559
17,929
2027
4,662
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.29
-1.09
-3.08
-4.48
-8
2026
-3.94
-1
-3.2
-2.57
-10.31
2027
7.09
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
1.51
2026
- -
- -
- -
- -
0.21
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Indoco Remedies Limited is an integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of active pharmaceutical ingredients (APIs) and finished dosage formulations across therapeutic areas including anti-infectives, cardiovasculars, gastrointestinals, and pain management. The company offers a diverse portfolio of branded generics and prescription drugs in categories such as tablets, capsules, injectables, and ophthalmics; key brands include Citalop, Redipred, and Emcor; it also provides contract manufacturing services and exports formulations to regulated markets. Founded in 1976 and headquartered in Mumbai, India, Indoco operates manufacturing facilities in India with a presence in over 50 countries, primarily targeting emerging and developed markets in Latin America, Africa, and Southeast Asia. In recent developments, Indoco Remedies expanded its product pipeline with the launch of new formulations in dermatology and respiratory segments in 2024, alongside receiving US FDA approvals for additional generic injectables. The company strengthened its global footprint through a strategic partnership with a leading Latin American distributor for anti-infective products in early 2025 and completed a funding round to bolster R&D investments in complex generics. These initiatives reflect ongoing efforts to diversify beyond domestic sales, which account for a significant portion of revenue, while navigating regulatory enhancements at its Goa facility.